

Supplementary Table 1. Correlation between TLR9 expression and clinical outcomes in HNSCC patients

Patient characteristics	Total (n=520)	TLR9 expression		P-value
		Low TLR9 (n=236)	High TLR9 (n=284)	
Gender				
Female	26.2% (136)	24.6% (58)	27.5% (78)	P>0.9999
Male	73.8% (384)	75.4% (178)	72.5% (206)	
Median age at diagnosis (Range)	61 (19-90)	61 (24-88)	60 (19-90)	-
Clinical stage				
I	3.8% (20)	1.7% (4)	5.6% (16)	P=0.99
II	18.8% (98)	20.3% (48)	17.6% (50)	
III	20.2% (105)	22.0% (52)	18.7% (53)	
IV	54.4% (283)	52.5 (124)	56% (159)	
Unknown	2.7% (14)	3.4% (8)	2.1% (6)	
Primary therapy outcome success				
Complete remission/response	71.5% (372)	69.9% (165)	72.9% (207)	P=0.97
Partial remission/response	1.2% (6)	0.8% (2)	1.4% (4)	
Persistent disease	0.8% (4)	1.3% (3)	0.4% (1)	
Progressive disease	7.5% (39)	9.3% (22)	6.0% (17)	
Stable disease	1.2% (6)	0.4% (1)	1.8% (5)	
Unknown	17.9% (93)	18.2% (43)	17.6% (50)	
Follow up treatment success				
Complete remission/response	43.6% (227)	41.1% (97)	45.8% (130)	P=0.98
Partial remission/response	1.0% (5)	1.3% (3)	0.7% (2)	
Persistent disease	2.3% (12)	2.1% (5)	2.5% (7)	
Progressive disease	14.4% (75)	14.8% (35)	14.1% (40)	
Stable disease	1.3% (7)	0.8% (2)	1.8% (5)	
Unknown	37.3% (194)	39.8% (94)	35.2% (100)	
HPV status				
Negative	14.0% (73)	11.9% (28)	15.8% (45)	P>0.99
Positive	7.3% (38)	3.4% (8)	10.6% (30)	
Unknown	78.6% (409)	84.7% (200)	73.6% (209)	
Radiation therapy				
Yes	56% (291)	57.2% (135)	54.9% (156)	P=0.98
No	30.6% (159)	28.8% (68)	32% (91)	
Unknown	13.5% (70)	14% (33)	13% (37)	
Targeted molecular therapy				
Yes	28.5% (148)	24.2% (57)	32% (91)	P=0.99
No	50% (260)	52.1% (123)	48.2% (137)	
Unknown	21.5% (112)	23.7% (56)	19.7% (56)	